We use cookies
BostonGene logo

Accelerating drug development with integrated omnimodal AI

BostonGene and Johnson & Johnson collaborate to optimize treatment sequencing and patient tolerability
Learn more
Partnership with Johnson Johnson Partnership with Johnson Johnson Partnership with Johnson Johnson
BostonGene and Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics
Learn more
Partnership with Daiichi Sankyo Partnership with Daiichi Sankyo Partnership with Daiichi Sankyo
BostonGene and AstraZeneca partner to transform AI-guided oncology development
Learn more
Partnership with AstraZeneca Partnership with AstraZeneca Partnership with AstraZeneca
BostonGene and Ottimo Pharma partner to streamline pioneering cancer immunotherapy
Learn more
Partnership with Ottimo Pharma Partnership with Ottimo Pharma Partnership with Ottimo Pharma
BostonGene optimizes oncology pipelines through AI-powered insights from tumor and immune biology
Learn more
Immune biology Immune biology Immune biology

Case studies

Prioritize indications and subtypes based on molecular signals
AI and digital twins predict therapy response and unlock high-value indications
Learn more
Stratify patients and optimize trials with AI-driven classifiers
AI classifier enables leaner trials with precise patient targeting
Learn more
Identify BTK-inh responder cohort to support label expansion
AI reveals responder cohorts to accelerate label expansion opportunities
Learn more

BostonGene AI platform BostonGene AI platform BostonGene AI platform BostonGene AI platform Learn more

Awards

Advancing precision medicine with global leaders

Johnson & Johnson
The partnership reflects BostonGene’s commitment to improving patient outcomes through innovative research and data-driven approaches.
Takeda
Takeda will leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials to enhance trial design, identify biomarker signatures for response and toxicity.
Ottimo Pharma
BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI.
AstraZeneca
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development.
View all partners